scispace - formally typeset
J

James McIntyre

Researcher at University of Cape Town

Publications -  307
Citations -  16124

James McIntyre is an academic researcher from University of Cape Town. The author has contributed to research in topics: Population & Men who have sex with men. The author has an hindex of 60, co-authored 298 publications receiving 14840 citations. Previous affiliations of James McIntyre include University of the Witwatersrand & Chris Hani Baragwanath Hospital.

Papers
More filters
Journal ArticleDOI

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

TL;DR: Early HIV diagnosis and early antiretroviral therapy reduced early infant mortality by 76% and HIV progression by 75%.
Journal ArticleDOI

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.

TL;DR: In this article, the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners was evaluated in a randomised placebo-controlled trial that enrolled heterosexual African adults who were seropositive for both HIV and herpes simplex virus type 2.
Journal ArticleDOI

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

TL;DR: Daily acyclovir therapy did not reduce the risk of transmission of HIV-1, despite a reduction in plasma HIV- 1 RNA of 0.25 log(10) copies per milliliter and a 73% reduction in the occurrence of genital ulcers due to HSV-2.
Journal ArticleDOI

A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.

TL;DR: In this paper, the efficacy and safety of two inexpensive and easily deliverable antiretroviral (ARV) regimens for the prevention of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) type 1 during labor and delivery HIV-infected pregnant women were screened at 11 maternity health institutions in South Africa and were enrolled in an open-label short course ARV regimen of either nevirapine (Nvp) or multiple-dose zidovudine and lamivudine (Zdv/3TC